NO20073813L - Kladribinregime for behandling av multippel sklerose - Google Patents

Kladribinregime for behandling av multippel sklerose

Info

Publication number: NO20073813L
Authority: NO; Norway
Prior art keywords: multiple sclerosis; treatment; cladribine; regimen; cladribine regimen
Prior art date: 2004-12-22

Application number

NO20073813A

Other languages

English (en)

Norwegian (no)

Inventor

Giampiero De Luca

Original Assignee

Serono Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2007-07-20

Publication date

2007-09-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073813(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-20 Application filed by Serono Lab filed Critical Serono Lab

2007-09-21 Publication of NO20073813L publication Critical patent/NO20073813L/no

Links

201000006417 multiple sclerosis Diseases 0.000 title abstract 3
238000011282 treatment Methods 0.000 title abstract 3
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title abstract 2
229960002436 cladribine Drugs 0.000 title abstract 2
208000007118 chronic progressive multiple sclerosis Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
201000008628 secondary progressive multiple sclerosis Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20073813A 2004-12-22 2007-07-20 Kladribinregime for behandling av multippel sklerose NO20073813L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US63866904P	2004-12-22	2004-12-22
EP04106909		2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en)	2004-12-22	2005-12-20	Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number	Publication Date
NO20073813L true NO20073813L (no)	2007-09-21

Family

ID=36227798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20073813A NO20073813L (no)	2004-12-22	2007-07-20	Kladribinregime for behandling av multippel sklerose

Country Status (25)

Country	Link
US (2)	US7713947B2 (lt)
EP (7)	EP3332789B1 (lt)
JP (7)	JP5795456B2 (lt)
KR (1)	KR20070091662A (lt)
AR (1)	AR052830A1 (lt)
AU (2)	AU2005318190B2 (lt)
BR (1)	BRPI0517132B8 (lt)
CA (2)	CA2588966C (lt)
CY (3)	CY1112614T1 (lt)
DK (3)	DK3332789T3 (lt)
EA (1)	EA015799B1 (lt)
ES (2)	ES2921858T3 (lt)
FI (1)	FI4070800T3 (lt)
FR (1)	FR18C1008I2 (lt)
HR (1)	HRP20120228T1 (lt)
HU (3)	HUE070333T2 (lt)
IL (2)	IL183930A0 (lt)
LT (3)	LT4070800T (lt)
LU (1)	LUC00064I2 (lt)
MX (1)	MX2007007610A (lt)
NO (1)	NO20073813L (lt)
PL (4)	PL2805723T3 (lt)
SG (1)	SG160391A1 (lt)
SI (3)	SI2805723T1 (lt)
WO (1)	WO2006067141A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0517132B8 (pt)	2004-12-22	2021-05-25	Laboratoires Serono S A	uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
CA2649810A1 (en) *	2006-05-24	2007-11-29	Laboratoires Serono S.A.	Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en)	2009-12-23	2011-07-13	Merck Serono S.A.	Use of purine analogues for treating airway diseases
WO2011117267A1 (en)	2010-03-24	2011-09-29	Merck Serono Sa	Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en)	2010-09-08	2012-03-14	Merck Serono S.A.	Oral administration of nucleoside monophosphates
WO2012097867A1 (en)	2011-01-18	2012-07-26	Synthon Bv	Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en)	2014-01-29	2014-03-12	Roach Arthur H	Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en)	2017-07-21	2019-01-23	Chord Therapeutics S A R L	Use of cladribine for treating autoimmune neuromuscular disease
CN119097635A (zh) *	2017-11-24	2024-12-10	默克专利股份公司	用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
US20240226284A1 (en)	2020-09-10	2024-07-11	Merck Patent Gmbh	Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) *	2020-12-10	2022-06-15	Chord Therapeutics S A R L	Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1269659A (en)	1984-08-06	1990-05-29	Brigham Young University	Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) *	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) *	1988-06-27	1990-10-23	Bloom Philip M	Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en)	1991-12-18	1993-05-04	Ortho Pharmaceutical Corporation	Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en)	1994-12-21	1997-06-24	Ortho Pharmaceutical Corporation	Stable 2-chloro-2'-deoxyadenosine formulations
JPH10512549A (ja)	1994-12-22	1998-12-02	オーソ・フアーマシユーチカル・コーポレーシヨン	可溶性の２−クロロ−２’−デオキシアデノシン配合物
US6194395B1 (en)	1999-02-25	2001-02-27	Orthro-Mcneil Pharmaceutical, Inc.	Cyclodextrin cladribine formulations
WO2000064918A1 (en)	1999-04-28	2000-11-02	Sterrenbeld Biotechnologie North America, Inc.	METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) *	2002-08-13	2004-03-04	Medac Gesellschaft für klinische Spezialpräparate mbH	Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
EP1556400B1 (en)	2002-09-25	2013-05-01	Brigham Young University	Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine
GB2394658A (en) *	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
EP1596873A1 (en) *	2003-02-25	2005-11-23	Applied Research Systems ARS Holding N.V.	Combined use of ribavirin and interferon beta in demyelinating diseases
ES2584183T3 (es)	2003-03-28	2016-09-26	Ares Trading S.A.	Formulaciones de cladribina para suministro mejorado oral y transmucosa
HRP20050925A2 (en)	2003-03-28	2006-08-31	Ivax Corporation	Oral formulations of cladribine
BRPI0517132B8 (pt)	2004-12-22	2021-05-25	Laboratoires Serono S A	uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
CA2649810A1 (en) *	2006-05-24	2007-11-29	Laboratoires Serono S.A.	Cladribine regimen for treating multiple sclerosis

2005
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en not_active Withdrawn
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Revoked
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending

Also Published As

Publication number	Publication date
LTPA2018503I1 (lt)	2018-03-12
JP6092945B2 (ja)	2017-03-08
CA3087419C (en)	2023-03-07
CY1119790T1 (el)	2018-06-27
EP4070800B1 (en)	2024-10-16
CY2018006I1 (el)	2018-06-27
EP4070800A1 (en)	2022-10-12
US7713947B2 (en)	2010-05-11
DK2805723T3 (da)	2018-01-29
LT4070800T (lt)	2025-01-10
EP2805723B1 (en)	2018-01-17
JP5795456B2 (ja)	2015-10-14
JP5908863B2 (ja)	2016-04-26
US8377903B2 (en)	2013-02-19
EP1827461A1 (en)	2007-09-05
ES3007339T3 (en)	2025-03-19
FR18C1008I2 (fr)	2019-03-01
CA2588966C (en)	2020-07-21
AU2011200768A1 (en)	2011-03-17
EP1827461B1 (en)	2012-02-29
JP2015180685A (ja)	2015-10-15
LUC00064I1 (lt)	2018-02-14
CA3087419A1 (en)	2006-06-29
AR052830A1 (es)	2007-04-04
EP2275110A2 (en)	2011-01-19
JP2020193206A (ja)	2020-12-03
PL1827461T3 (pl)	2012-07-31
EP3332789B1 (en)	2022-04-06
EP2263678A2 (en)	2010-12-22
MX2007007610A (es)	2007-08-03
HUE070333T2 (hu)	2025-05-28
LUC00064I2 (lt)	2018-03-28
AU2005318190B2 (en)	2010-11-25
CA2588966A1 (en)	2006-06-29
AU2011200768B2 (en)	2012-09-13
AU2005318190A1 (en)	2006-06-29
BRPI0517132A (pt)	2008-09-30
US20100203017A1 (en)	2010-08-12
IL212421A (en)	2014-01-30
EA200701221A1 (ru)	2008-02-28
SI2805723T1 (en)	2018-02-28
LTC2805723I2 (lt)	2022-04-25
FR18C1008I1 (lt)	2018-03-30
FI4070800T3 (fi)	2025-01-14
PL4070800T3 (pl)	2025-03-10
EP2275110A3 (en)	2011-04-27
EP4523753A3 (en)	2025-05-28
JP2017101061A (ja)	2017-06-08
EP4523753A2 (en)	2025-03-19
JP6290962B2 (ja)	2018-03-07
JP2008524313A (ja)	2008-07-10
EP2263678A3 (en)	2011-04-27
EA015799B1 (ru)	2011-12-30
JP2013216664A (ja)	2013-10-24
PL3332789T3 (pl)	2022-08-22
KR20070091662A (ko)	2007-09-11
CY1112614T1 (el)	2016-02-10
BRPI0517132B8 (pt)	2021-05-25
SG160391A1 (en)	2010-04-29
HUS1800009I1 (hu)	2018-05-02
ES2921858T3 (es)	2022-09-01
EP2275110B1 (en)	2013-07-10
BRPI0517132B1 (pt)	2020-02-18
WO2006067141A1 (en)	2006-06-29
JP6430554B2 (ja)	2018-11-28
IL212421A0 (en)	2011-06-30
SI3332789T1 (sl)	2022-08-31
LT3332789T (lt)	2022-07-25
CY2018006I2 (el)	2018-06-27
EP3332789A1 (en)	2018-06-13
JP2016138128A (ja)	2016-08-04
JP2018165271A (ja)	2018-10-25
IL183930A0 (en)	2007-10-31
PL2805723T3 (pl)	2018-04-30
SI4070800T1 (sl)	2025-03-31
EP2805723A1 (en)	2014-11-26
HRP20120228T1 (hr)	2012-04-30
HUE059133T2 (hu)	2022-10-28
EP2263678B1 (en)	2014-06-11
US20090081163A1 (en)	2009-03-26
DK3332789T3 (da)	2022-07-11
DK4070800T3 (da)	2025-01-02

Legal Events

Date	Code	Title	Description
2015-07-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
GEP20084452B (en)	2008-08-10	Sulfonamide derivatives for the treatment of diseases
CY1111470T1 (el)	2015-08-05	Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200700362A1 (ru)	2008-08-29	Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
NO20043367L (no)	2004-08-13	Oralt farmasoytisk preparat
NO20081844L (no)	2008-05-29	Terapeutiske forbindelser
EA201071039A1 (ru)	2011-02-28	Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
NO20064186L (no)	2006-11-14	Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
EA201291089A1 (ru)	2013-05-30	Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
EA201300420A1 (ru)	2013-09-30	Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
NO20064078L (no)	2006-09-11	Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
AU2020278236A8 (en)	2022-04-28	Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
EA202191955A1 (ru)	2021-10-07	Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
NO20082047L (no)	2008-04-29	Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
PH12021553056A1 (en)	2023-09-11	Modified release formulations and uses thereof
SE0303480D0 (sv)	2003-12-19	Benzofuranes
SG160391A1 (en)	2010-04-29	Cladribine regimen for treating multiple sclerosis
UA91485C2 (ru)	2010-07-26	лечебно-профилактическАЯ смесЬ для ухода за полостью рта
JP2009505991A5 (lt)	2009-08-20
CY1111361T1 (el)	2015-08-05	Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
BRPI0516545A (pt)	2008-09-09	uso de óleo de lavanda para a profilaxia e tratamento de neurastenia, distúrbios de somatização e outras doenças associadas ao estresse
JP2012097034A5 (lt)	2013-10-31
PT3332789T (pt)	2022-07-05	Regime de cladribina para o tratamento de esclerose múltipla
JOP20200005B1 (ar)	2024-04-18	تركيبات صيدلية
WO2006047162A3 (en)	2006-09-21	Compositions and methods for treatment of disease caused by yersinia spp infection